Aethlon Medical (NASDAQ:AEMD) Coverage Initiated at

Stock analysts at initiated coverage on shares of Aethlon Medical (NASDAQ:AEMDGet Free Report) in a report issued on Monday. The brokerage set a “sell” rating on the medical equipment provider’s stock.

Separately, HC Wainwright cut their price target on Aethlon Medical from $90.00 to $23.00 and set a “buy” rating for the company in a research note on Tuesday, October 24th.

View Our Latest Report on Aethlon Medical

Aethlon Medical Trading Down 5.5 %

Shares of Aethlon Medical stock opened at $1.63 on Monday. The business’s fifty day simple moving average is $1.90 and its 200 day simple moving average is $2.89. Aethlon Medical has a 12 month low of $1.40 and a 12 month high of $8.70. The firm has a market capitalization of $4.04 million, a P/E ratio of -0.34 and a beta of 1.39.

Institutional Trading of Aethlon Medical

A number of hedge funds have recently made changes to their positions in AEMD. Two Sigma Investments LP bought a new stake in Aethlon Medical during the third quarter worth about $32,000. Renaissance Technologies LLC purchased a new position in shares of Aethlon Medical during the 3rd quarter valued at about $36,000. HRT Financial LP bought a new stake in Aethlon Medical in the 4th quarter worth approximately $28,000. Citadel Advisors LLC purchased a new stake in Aethlon Medical in the third quarter worth approximately $72,000. Finally, Jane Street Group LLC grew its position in Aethlon Medical by 895.7% during the fourth quarter. Jane Street Group LLC now owns 140,245 shares of the medical equipment provider’s stock valued at $39,000 after acquiring an additional 126,160 shares during the last quarter. 3.02% of the stock is owned by institutional investors.

Aethlon Medical Company Profile

(Get Free Report)

Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses from the human circulatory system.

Featured Stories

Receive News & Ratings for Aethlon Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aethlon Medical and related companies with's FREE daily email newsletter.